Gene therapy for stimulation of angiogenesis
CA 2307953 A1 · Owner: Merck & Co. Inc. · Inventors: Thomas, Kenneth A. Jr.; Bett, Andrew J.; Huckle, William R.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to methods of gene therapy to promote angiogenesis in the treatment of peripheral cardiac and other pathological , tissue ischemias utilizing a DNA molecule (SEQ ID NO:1) which encodes human VEGF145, set forth in SEQ ID NO:2.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 23, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 23, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 23, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.